Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) had Return on Tangible Equity of -110.83% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-8.42M |
|
-- |
|
-- |
|
$11.40M |
|
$-11.40M |
|
$2.84M |
|
$-8.56M |
|
$-8.56M |
|
$-8.42M |
|
$-8.42M |
|
$-8.42M |
|
$-8.42M |
|
$-11.40M |
|
$-11.15M |
|
0.11M |
|
0.11M |
|
$-76.73 |
|
$-76.73 |
|
| Balance Sheet Financials | |
$16.41M |
|
$0.12M |
|
$7.56M |
|
$23.97M |
|
$8.08M |
|
-- |
|
$0.85M |
|
$8.93M |
|
$15.04M |
|
$7.60M |
|
$15.04M |
|
0.45M |
|
| Cash Flow Statement Financials | |
$-7.37M |
|
$-0.77M |
|
$17.19M |
|
$2.20M |
|
$11.25M |
|
$9.05M |
|
$0.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.03 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.35M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-55.98% |
|
|
Return on Tangible Equity |
-110.83% |
-35.12% |
|
-55.98% |
|
$33.30 |
|
$-67.00 |
|
$-67.20 |
|